[Clinical study of immunotherapy for bronchial asthma using purified mite feces antigen].
For many years, hyposensitization therapy was considered to be a radical therapy for allergic diseases such as bronchial asthma. Adverse effects including the inducement of asthma attacks or anaphylactic shock were attributed to the use of crude antigen solution during treatment. To contribute to the establishment of safer and more effective approaches, we conducted immunotherapy trials using purified mite feces antigen. Among the antigen fractions that were separated and purified for this purpose, the HM 2 antigen fraction with a molecular weight in the 30-40 kD range was found to be the most suitable for use. Treatment utilizing this fraction achieved favorable outcomes. Of 25 patients with nonseasonal asthma, the clinical outcome of treatment was "markedly improved" in 7, "moderately improved" in 11, "slightly improved" in 3, "unchanged" in 4, and "worsened" in none. Also, 4 of 5 patients with seasonal asthma experienced a cessation of seasonal attacks. Among factors that affect therapeutic efficacy, high Df-RAST scores and a history of childhood asthma were considered to be particularly important.